CABG

Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Retrieved on: 
Thursday, March 7, 2024

TORONTO, March 07, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient recruitment and dosing has begun in Turkey for the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).

Key Points: 
  • TORONTO, March 07, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient recruitment and dosing has begun in Turkey for the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).
  • LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
  • The Arch Biopartners team is currently working with hospital sites in Canada to prepare for their participation in this Phase II trial.
  • The CS-AKI Phase II trial is an international multi-center, randomized, double-blind, placebo-controlled study of LSALT peptide.

Lee Health’s HealthPark Medical Center Named Among the Top 50 Hospitals for Heart Care in the U.S. for the 11th Time

Retrieved on: 
Tuesday, February 20, 2024

Formerly known as the IBM Watson award, the PINC AI™ 50 Top Cardiovascular Hospitals™ represent the highest standard of cardiovascular care in the United States.

Key Points: 
  • Formerly known as the IBM Watson award, the PINC AI™ 50 Top Cardiovascular Hospitals™ represent the highest standard of cardiovascular care in the United States.
  • HealthPark Medical Center is one of only five hospitals in Florida and the only hospital in Southwest Florida to earn the designation.
  • The 2024 PINC AI™ 50 Top Cardiovascular Hospitals™ provide higher quality clinical care and are more efficient than their peers.
  • The PINC AI™ 50 Top Cardiovascular Hospitals™ program focuses on short-term, acute care, non-federal U.S. hospitals that treat a broad spectrum of cardiology patients.

PINC AI™ and Fortune Name the Nation’s 50 Top Cardiovascular Hospitals™

Retrieved on: 
Thursday, February 15, 2024

PINC AI™, the technology and services brand of Premier, Inc. (NASDAQ: PINC), today announced the nation’s 50 Top Cardiovascular Hospitals™.

Key Points: 
  • PINC AI™, the technology and services brand of Premier, Inc. (NASDAQ: PINC), today announced the nation’s 50 Top Cardiovascular Hospitals™.
  • To create the list, an objective, quantitative analysis of publicly available data was conducted to identify the top cardiovascular hospitals in the United States.
  • The primary purpose of the PINC AI™ 50 Top Cardiovascular Hospitals™ program is to inspire hospital and health system leaders to pursue higher performance and deliver added value to patients and communities.
  • Compared to their peers, this year’s top performers had:
    28 percent fewer acute myocardial infarction (AMI) deaths and 50 percent fewer coronary artery bypass grafting (CABG) deaths.

MemorialCare Heart & Vascular Institute at Orange Coast Medical Center Earns 4 out of 5 Three-Star Ratings for Coronary Artery Bypass Surgery

Retrieved on: 
Monday, January 29, 2024

FOUNTAIN VALLEY, Calif., Jan. 29, 2024 /PRNewswire/ -- MemorialCare Orange Coast Medical Center cardiac surgeons have earned distinguished three-star ratings from The Society of Thoracic Surgeons (STS) for its patient care and outcomes in isolated coronary artery bypass grafting (CABG) procedures.  The three-star ratings were awarded in the categories of medication compliance, absence of morbidity, absence of mortality, and overall composite score. The three-star accolades denote the highest category of quality and place Orange Coast Medical Center among the elite cardiothoracic surgery programs in the United States and Canada.

Key Points: 
  • The three-star ratings were awarded in the categories of medication compliance, absence of morbidity, absence of mortality, and overall composite score.
  • The three-star accolades denote the highest category of quality and place Orange Coast Medical Center among the elite cardiothoracic surgery programs in the United States and Canada.
  • The star rating is calculated using a combination of quality measures for specific procedures performed by an STS Adult Cardiac Surgery Database participant.
  • Some important measures include absence of morbidity and mortality, percentage of rapid extubation, and use of arterial conduits.

Arch Biopartners Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Retrieved on: 
Wednesday, January 10, 2024

TORONTO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it has received a No Objection Letter from Health Canada to conduct a Phase II trial for LSALT peptide, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).

Key Points: 
  • TORONTO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it has received a No Objection Letter from Health Canada to conduct a Phase II trial for LSALT peptide, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).
  • LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
  • The Phase II trial is an international multi-center, randomized, double-blind, placebo-controlled study of LSALT peptide.
  • There is no treatment available in the market today that prevents acute kidney injury of the type commonly experienced by on-pump cardiac surgery patients.

Providence Mission Hospital Receives 2024 Healthgrades Cardiac Surgery Excellence Award for Third Consecutive Year

Retrieved on: 
Thursday, January 4, 2024

The Providence Mission Hospital Heart and Vascular Institute has been awarded the 2024 Healthgrades Cardiac Surgery Excellence Award for the third consecutive year, and it is among the top 10% of hospitals in the nation for cardiac surgery.

Key Points: 
  • The Providence Mission Hospital Heart and Vascular Institute has been awarded the 2024 Healthgrades Cardiac Surgery Excellence Award for the third consecutive year, and it is among the top 10% of hospitals in the nation for cardiac surgery.
  • The hospital is also a Five-Star recipient for Coronary Bypass Surgery for the second year in a row and a Five-Star recipient for the treatment of pulmonary embolisms.
  • The Healthgrades Cardiac Surgery Excellence Award highlights hospitals that deliver superior patient outcomes in heart bypass and heart valve surgery.
  • “The cardiac surgery team at Mission Hospital is comprised of the most extraordinary clinicians – it is truly an honor to serve alongside them to care for our South Orange County neighbors,” said Dr. Sevak Darbinian, chief of cardiothoracic surgery at Providence Mission Hospital since 2008.

Arch Biopartners Receives Approval from the Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Retrieved on: 
Wednesday, January 3, 2024

TORONTO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it has received approval in Turkey from the Ministry of Health to proceed with a Phase II trial for LSALT peptide, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).

Key Points: 
  • TORONTO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it has received approval in Turkey from the Ministry of Health to proceed with a Phase II trial for LSALT peptide, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).
  • LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
  • With the Ministry of Health (MoH) approval for the trial, Arch can now proceed to contract and activate clinical sites in Turkey.
  • Once blood flow is restored to normal (reperfusion), inflammation is triggered and injury to kidney cells is exacerbated.

CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation

Retrieved on: 
Thursday, December 28, 2023

The independent DSMB met recently to perform the final review of the full unblinded data on all 140 patients in the STAR-T trial and concluded there were no issues with device safety, meeting the primary safety endpoint of the study.

Key Points: 
  • The independent DSMB met recently to perform the final review of the full unblinded data on all 140 patients in the STAR-T trial and concluded there were no issues with device safety, meeting the primary safety endpoint of the study.
  • The Company expects to complete the analysis of the full trial results in the next several weeks.
  • Pending this final analysis, the Company believes the safety and effectiveness data from STAR-T may support the regulatory submission of DrugSorb-ATR to the U.S. FDA and Health Canada.
  • If accepted, the full results of the STAR-T trial are expected to be presented next April 2024 in Atlanta.

Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Retrieved on: 
Thursday, December 21, 2023

LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.

Key Points: 
  • LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
  • The ethics committee approval of the trial will be followed by a final regulatory review conducted by the Turkish Ministry of Health (MoH), expected to be completed by mid-January.
  • Once the trial is approved by the MoH, activation of clinical sites in Turkey will take place and patient enrollment can begin in February.
  • Quote from Richard Muruve, CEO of Arch Biopartners Inc:
    “We look forward to a positive decision from the MoH, which will permit enrollment of Turkish cardiac surgery patients into the trial.

Arch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Retrieved on: 
Wednesday, December 13, 2023

LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.

Key Points: 
  • LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
  • The FDA granted the Company permission to proceed with a Phase II trial in late June .
  • Quote from Richard Muruve, CEO of Arch Biopartners Inc:
    “The clinical trial application submitted to Health Canada is the result of clinical interest in Canada to support our Phase II trial targeting CS-AKI.
  • LSALT peptide has been shown to prevent ischemia reperfusion injury (IRI) to the kidneys in pre-clinical models , providing the scientific rationale for Arch to use LSALT peptide in this CS-AKI trial.